72733-86-9

Usage

Uses

Used in Pharmaceutical Industry:
(R,S)-3-cyclohexyl-butyl-4-aminobutyric acid is used as a therapeutic agent for the treatment of anxiety, epilepsy, and neuropathic pain. Its GABA receptor agonist properties allow it to modulate the inhibitory neurotransmission in the central nervous system, potentially providing relief from these conditions.
Used in Research and Development:
(R,S)-3-cyclohexyl-butyl-4-aminobutyric acid is used as a research compound for studying the function and modulation of GABA receptors. This can lead to the development of new drugs and therapies for various neurological and psychiatric disorders.
Used in Drug Design and Optimization:
The stereochemistry of (R,S)-3-cyclohexyl-butyl-4-aminobutyric acid, with both R and S enantiomers, provides an opportunity for drug design and optimization. Understanding the pharmacological activity and potential side effects of each enantiomer can help in the development of more effective and safer drugs targeting the GABA receptor system.

Upstream product

• 2043-61-0 cyclohexanecarbaldehyde 
• 26429-99-2 methyl (2E)-3-cyclohexylprop-2-enoate 

Relevant academic research and scientific papers

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt- Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.